Apellis Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$196,830
$199,685
$172,325
$146,377
Gross Profit
163,273
176,136
151,672
126,465
EBITDA
-43,864
-27,735
-58,842
-79,261
EBIT
-44,321
-28,184
-59,286
-79,751
Net Income
-57,445
-37,657
-66,423
-88,576
Net Change In Cash
196,830
199,685
172,325
146,377
Free Cash Flow
34,096
-8,429
-133,276
-97,970
Cash
396,864
361,426
327,026
352,299
Basic Shares
123,904
123,904
122,957
121,232

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$396,591
$75,422
$66,563
$250,646
Gross Profit
338,081
69,786
61,363
225,596
EBITDA
-495,211
-617,390
-731,269
-312,233
EBIT
-496,915
-618,877
-732,761
-313,092
Net Income
-528,628
-652,172
-746,354
-344,874
Net Change In Cash
396,591
75,422
66,563
250,646
Free Cash Flow
-595,508
-515,269
-564,229
-165,910
Cash
351,185
551,801
640,192
565,779
Basic Shares
118,678
106,114
84,421
75,163

Earnings Calls

Quarter EPS
2024-09-30
-$0.46
2024-06-30
-$0.28
2024-03-31
-$0.42
2023-12-31
-$0.73